These results prompted us to investigate whether DDA1 participated in stage II colon cancer tumorigenesis and tumor recurrence via the modulation of NFκB/CSN2/GSK3β signaling, and could serve as a prognostic biomarker. Here, CSN2 is linked to neoplasm.